5,468
Views
24
CrossRef citations to date
0
Altmetric
Clinical Features - <italic>Original Research</italic>

Lack of residual morning effects of lemborexant treatment for insomnia: summary of findings across 9 clinical trials

ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon & ORCID Icon show all
Pages 71-81 | Received 12 Jul 2020, Accepted 11 Sep 2020, Published online: 29 Oct 2020

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (4)

Maria P Mogavero, Alessandro Silvani, Giuseppe Lanza, Lourdes M DelRosso, Luigi Ferini-Strambi & Raffaele Ferri. (2023) Targeting Orexin Receptors for the Treatment of Insomnia: From Physiological Mechanisms to Current Clinical Evidence and Recommendations. Nature and Science of Sleep 15, pages 17-38.
Read now
Phoebe Tall, Mubasher A Qamar, Ivana Rosenzweig, Vanessa Raeder, Anna Sauerbier, Zach Heidemarie, Cristian Falup-Pecurariu & Kallol Ray Chaudhuri. (2023) The Park Sleep subtype in Parkinson’s disease: from concept to clinic. Expert Opinion on Pharmacotherapy 24:15, pages 1725-1736.
Read now
Russell Rosenberg, Leslie Citrome & Christopher L Drake. (2021) Advances in the Treatment of Chronic Insomnia: A Narrative Review of New Nonpharmacologic and Pharmacologic Therapies. Neuropsychiatric Disease and Treatment 17, pages 2549-2566.
Read now
Gary Zammit & Andrew Krystal. (2021) Evaluating lemborexant for the treatment of insomnia. Expert Opinion on Pharmacotherapy 22:10, pages 1235-1243.
Read now

Articles from other publishers (20)

Kyohei Ueno, Hitoaki Sato, Yuki Nomura, Norihiko Obata & Satoshi Mizobuchi. (2024) Improvement of sleep and pain with lemborexant administration in patients with chronic pain: a retrospective observational study. Pain Medicine 25:2, pages 139-143.
Crossref
Pesala Pavan Kumar Reddy, Jayasheela S Hiremath, Sanatkumar Bharamu Nyamagoud & Agadi Hiremath Viswanatha Swamy. (2024) A comprehensive review of the use of lemborexant in treating insomnia. MGM Journal of Medical Sciences 11:1, pages 146-151.
Crossref
Michele Fornaro, Claudio Caiazza, Giuseppe De Simone, Flavia Rossano & Andrea de Bartolomeis. (2024) Insomnia and related mental health conditions: Essential neurobiological underpinnings towards reduced polypharmacy utilization rates. Sleep Medicine 113, pages 198-214.
Crossref
Clemens Muehlan, Catherine Roch, Cedric Vaillant & Jasper Dingemanse. (2023) The orexin story and orexin receptor antagonists for the treatment of insomnia. Journal of Sleep Research 32:6.
Crossref
Sho Horikoshi, Itaru Miura, Yuhei Suzuki, Yuri Kobayashi, Yoichiro Hirata, Masayuki Goto, Mizue Ichinose, Shinnosuke Yamamoto, Keiko Kanno-Nozaki, Kenya Watanabe & Hirooki Yabe. (2023) Switching to lemborexant for the management of insomnia in mental disorders: the SLIM study. Journal of Clinical Sleep Medicine 19:10, pages 1753-1758.
Crossref
Masakazu Terauchi, Jocelyn Y. Cheng, Jane Yardley, Kate Pinner, Margaret Moline, Manoj Malhotra, Kanako InabeMaika NishidaElizabeth Pappadopulos. (2023) Efficacy and safety of lemborexant in midlife women with insomnia disorder. Menopause 30:8, pages 839-848.
Crossref
Kazumaro Okino, Hirohisa Suzuki, Hiroi Tomioka, Kenji Sanada, Keita Kawai, Akira Iwanami & Atsuko Inamoto. (2023) Efficacy and safety of lemborexant as an alternative drug for patients with insomnia taking gamma‐aminobutyric acid–benzodiazepine receptor agonists or suvorexant. Human Psychopharmacology: Clinical and Experimental 38:3.
Crossref
Margaret Moline, Shoji Asakura, Carsten Beuckman, Ishani Landry, Beatrice Setnik, Judy Ashworth & Jack E. Henningfield. (2023) The abuse potential of lemborexant, a dual orexin receptor antagonist, according to the 8 factors of the Controlled Substances Act. Psychopharmacology 240:4, pages 699-711.
Crossref
Muzaffar Iqbal, Abdullah Alshememry, Faisal Imam, Mohd Abul Kalam, Ali Akhtar & Essam A. Ali. (2023) UPLC-MS/MS Based Identification and Quantification of a Novel Dual Orexin Receptor Antagonist in Plasma Samples by Validated SWGTOX Guidelines. Toxics 11:2, pages 109.
Crossref
Paula K. Schweitzer. 2023. Encyclopedia of Sleep and Circadian Rhythms. Encyclopedia of Sleep and Circadian Rhythms 411 420 .
Habibolah Khazaie, Masoud Sadeghi, Sepideh Khazaie, Max Hirshkowitz & Amir Sharafkhaneh. (2022) Dual orexin receptor antagonists for treatment of insomnia: A systematic review and meta-analysis on randomized, double-blind, placebo-controlled trials of suvorexant and lemborexant. Frontiers in Psychiatry 13.
Crossref
Amitabh Dash, Kate Pinner, Yuichi Inoue, Kenichi Hayashida, Sung Chul Lim, Chang-Ho Yun, Tsuo-Hung Lan, Chieh-Liang Huang, Jane Yardley, Naoki Kubota & Margaret Moline. (2022) Efficacy and safety of lemborexant over 12 months in Asian adults with insomnia disorder. Sleep Medicine: X 4, pages 100044.
Crossref
Baoding Zhou, Wenjian Zhao, Wenhao Guo, Linchao Li, Dejin Zhang, Qingzhou Mao & Qingquan Li. (2022) Smartphone-based road manhole cover detection and classification. Automation in Construction 140, pages 104344.
Crossref
Ishani Landry, Nancy Hall, Jagadeesh Alur, Gleb Filippov, Larisa Reyderman, Beatrice Setnik, Jack Henningfield & Margaret Moline. (2022) Acute Cognitive Effects of the Dual Orexin Receptor Antagonist Lemborexant Compared With Suvorexant and Zolpidem in Recreational Sedative Users. Journal of Clinical Psychopharmacology 42:4, pages 374-382.
Crossref
Ishani Landry, Nancy Hall, Jagadeesh Aluri, Gleb Filippov, Larisa Reyderman, Beatrice Setnik, Jack Henningfield & Margaret Moline. (2022) Abuse Potential of Lemborexant, a Dual Orexin Receptor Antagonist, Compared With Zolpidem and Suvorexant in Recreational Sedative Users. Journal of Clinical Psychopharmacology 42:4, pages 365-373.
Crossref
Ishani Landry, Nancy Hall, Jagadeesh Aluri, Gleb Filippov, Beatrice Setnik, Satish Dayal, Larisa Reyderman & Margaret Moline. (2022) Effect of alcohol coadministration on the pharmacodynamics, pharmacokinetics, and safety of lemborexant: A randomized, placebo-controlled crossover study. Journal of Psychopharmacology 36:6, pages 745-755.
Crossref
Laura H. Jacobson, Daniel Hoyer & Luis de Lecea. (2022) Hypocretins (orexins): The ultimate translational neuropeptides. Journal of Internal Medicine 291:5, pages 533-556.
Crossref
Taro Kishi, Maika Nishida, Michinori Koebis, Takehiro Taninaga, Kenzo Muramoto, Naoki Kubota, Margaret Moline, Kenji Sakuma, Makoto Okuya, Ikuo Nomura & Nakao Iwata. (2021) Evidence‐based insomnia treatment strategy using novel orexin antagonists: A review. Neuropsychopharmacology Reports 41:4, pages 450-458.
Crossref
Keisuke Suzuki. (2021) Current Update on Clinically Relevant Sleep Issues in Parkinson’s Disease: A Narrative Review. Journal of Parkinson's Disease 11:3, pages 971-992.
Crossref
Takashi Ueno, Yukiko Miyajima, Ishani Landry, Bojan Lalovic & Edgar Schuck. (2021) Physiologically‐based pharmacokinetic modeling to predict drug interactions of lemborexant with CYP3A inhibitors. CPT: Pharmacometrics & Systems Pharmacology 10:5, pages 455-466.
Crossref